Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Study protocol

A multicenter study investigating the molecular fingerprint of psychological resilience in breast cancer patients: study protocol of the SCAN-B resilience study

Authors: Ulrika Axelsson, Lisa Rydén, Per Johnsson, Patrik Edén, Johanna Månsson, Ingalill Rahm Hallberg, Carl A. K. Borrebaeck

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Individual patients differ in their psychological response when receiving a cancer diagnosis, in this case breast cancer. Given the same disease burden, some patients master the situation well, while others experience a great deal of stress, depression and lowered quality of life. Patients with high psychological resilience are likely to experience fewer stress reactions and better adapt to and manage the life threat and the demanding treatment that follows the diagnosis. If this phenomenon of mastering difficult situations is reflected also in biomolecular processes is not much studied, nor has its capacity for impacting the cancer prognosis been addressed.
This project specifically aims, for the first time, to investigate how a breast cancer patient’s psychological resilience is coupled to biomolecular parameters using advanced “omics” and, as a secondary aim, whether it relates to prognosis and quality of life one year after diagnosis.

Method

The study population consists of newly diagnosed breast cancer patients enrolled in the Sweden Cancerome Analysis Network – Breast (SCAN-B) at four hospitals in Sweden. At the time of cancer diagnosis, the patient fills out the standardized method to measure psychological resilience, the “Connor-Davidson Resilience scale” (CD-RISC), the quality of life measure SF-36, as well as providing social and socioeconomic variables. In addition, one blood sample is collected. At the one-year follow-up, the patient will be subjected to the same assessments, and we also collect information regarding smoking, exercise habits, and BMI, as well as patients’ trust in the treatment and their satisfaction with the care and treatment.

Discussion

This explorative hypothesis-generating project will pave the way for larger validation studies, potentially leading to a standardized method of measuring psychological resilience as an important parameter in cancer care. Revealing the body-mind interaction, in terms of psychological resilience and quality of life, will herald the development of truly personalized psychosocial care and cancer intervention treatment strategies.

Trial registration

This is a retrospectively registered trial at ClinicalTrials.gov, ID: NCT03430492 on February 6, 2018.
Appendix
Available only for authorised users
Literature
1.
Min JA, Yoon S, Lee CU, Chae JH, Lee C, Song KY, Kim TS. Psychological resilience contributes to low emotional distress in cancer patients. Support Care Cancer. 2013;21:2469–76.CrossRefPubMed
2.
Southwick SM, Vythilingam M, Charney DS. The psychobiology of depression and resilience to stress: implications for prevention and treatment. Ann Rev Clin Psychol. 2005;1:255–91.CrossRef
3.
Herrman H, Stewart DE, Diaz-Granados N, Berger EL, Jackson B, Yuen T. What is resilience? La Revue Canadienne de Psychiatrie. 2011;56:5.
4.
Lutgendorf SK, Sood AK, Antoni MH. Hostfactors and Cancer progression: Biobehavvioral signaling pathways and interventions. J Clin Oncol. 2010;28:4094–9.CrossRefPubMedPubMedCentral
5.
6.
7.
8.
Connor KM, Davidson JRT. Development of a new resilience scale: the Connor-Davidson resilience scale (CD-RISC). Depress Anxiety. 2003;18:76–82.CrossRefPubMed
9.
Connor KM, Davidson JRT, Lee L-C. Spirituality, resilience and anger in survivors of violen trauma: a community study. J Traumatic Stress. 2003;18:71–82.
10.
Craig A, Blumgart E, Tran Y. Resilience and stuttering: factors that protect people from the adversity of chronic stuttering. Speech Lang Hear Res. 2011;54:1485–96.CrossRef
11.
Ding Y, Bao LP, Xu H, Hallberg IR. Psychometric properties of the Chinese version of sense of coherence scale in women with cervical cancer. Psycho-Oncology. 2012;21:1205–14.CrossRefPubMed
12.
Saal LH, Vallon-Christersson J, Häkkinen J, Hegardt C, Grabau D, Winter C, Brueffer C, Tang MH, Reuterswärd C, Schulz R, Karlsson A, Ehinger A, Malina J, Manjer J, Malmberg M, Larsson C, Rydén L, Loman N, Borg Å. The Sweden Cancerome analysis network - breast (SCAN-B) initiative: a large-scale multicenter infrastructure towards implementation of breast cancer genomic analyses in the clinical routine. Genome Med. 2015;7(1):20.CrossRefPubMedPubMedCentral
13.
Rydén L, Loman N, Larsson C, Hegardt C, Vallon-Christersson J, Malmberg M, Lindman H, Ehinger A, Saal LH, Borg Å. Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative. Br J Surg. 2018;105:e158–68.CrossRefPubMedPubMedCentral
14.
Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36®): I. Conceptual framework and item selection. Med Care. 1992;30:473–83.CrossRefPubMed
15.
Sullivan M, Karlsson J, Ware JE. The Swedish SF-36® health survey: I. Evaluation of data quality, scaling assumption, reliability and construct validity across general populations in Sweden. Soc Sci Medical. 1995;41:1349–58.CrossRef
16.
17.
18.
Smith-Osborne A, Bolton K. Assessing resilience: review of measures across the life course. J Evidence-Based Social Work. 2013;10:111–26.CrossRef
19.
Sullivan M, Karlsson J, Taft C. SF-36 health survey: Swedish manual and interpretation guide. 2002.
20.
Jöreskog KG, Sörbom D. Advances in factor analysis and structural equation models. Cambridge, MA: Abt Books; 1979. p. 21–43.
21.
22.
Green KT, Hayward LC, Williams AM, Mid-Atlantic Mental Illness Research, Education and Clinical Center Workgroup, et al. Examining the factor structure of the Connor-Davidson resilience scale (CD-RISC) in a post-9/11 U.S. military veteran sample. Assessment. 2014;21:443–51.CrossRefPubMedPubMedCentral
23.
Roos JM. Ge extra stöd till ängsliga patienter. Onkologi i Sverige. 2016;2:32–5.
Metadata
Title
A multicenter study investigating the molecular fingerprint of psychological resilience in breast cancer patients: study protocol of the SCAN-B resilience study
Authors
Ulrika Axelsson
Lisa Rydén
Per Johnsson
Patrik Edén
Johanna Månsson
Ingalill Rahm Hallberg
Carl A. K. Borrebaeck
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4669-y

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ

Research article

Gut disruption impairs rehabilitation in patients curatively operated for pancreaticoduodenal cancer - a qualitative study

Research article

MAP3K7 is recurrently deleted in pediatric T-lymphoblastic leukemia and affects cell proliferation independently of NF-κB

Research article

The impact of pharmacokinetic gene profiles across human cancers

Research article

Microenvironment dependent gene expression signatures in reprogrammed human colon normal and cancer cell lines

Study protocol

Randomized clinical trial testing the efficacy and safety of 0.5% colchicine cream versus photodynamic therapy with methyl aminolevulinate in the treatment of skin field cancerization: study protocol
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits